Phase IIa Study on the Role of Gemcitabine Plus Romidepsin (GEMRO Regimen) in the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma Patients

Trial Profile

Phase IIa Study on the Role of Gemcitabine Plus Romidepsin (GEMRO Regimen) in the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma Patients

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Gemcitabine (Primary) ; Romidepsin (Primary)
  • Indications Peripheral T-cell lymphoma
  • Focus Therapeutic Use
  • Acronyms FIL-GEMRO
  • Most Recent Events

    • 28 Jan 2016 Planned End Date changed from 1 Sep 2015 to 1 Sep 2017 as reported by ClinicalTrials.gov record.
    • 08 Dec 2015 Status changed from recruiting to active, no longer recruiting as results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 28 Jan 2014 New source identified and integrated (European Clinical Trials Database).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top